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Research Inc, Burlington, ON, Canada
In an ideal world, appropriate pharmacoeconomic evi-
dence would be collected to meet the needs of the local
reimbursement environment. Unfortunately, due to clini-
cal research limitations and time constraints, we are often
faced with a lack of the necessary data. OBJECTIVE: Us-
ing an anti-infective as our case study, we present an ap-
proach that we developed to overcome the challenge of
creating an economic argument for Canadian hospital
setting in the absence of country-specific data. METH-
ODS: Our methodology involved a multi-step approach:
(i) hospital formulary committee members were con-
sulted to identify the submission requirements; (ii) a
panel of experts were surveyed to understand local treat-
ment patterns; (iii) the survey results were used in a case
modeling exercise to determine the applicability of the
randomized clinical trial (RCT) protocol to the Canadian
environment; and (iv) a chart review was undertaken to
validate results of the case modeling exercise. RESULTS:
Hospital formulary committees preferred Canadian-spe-
cific evidence of a new product’s economic value. Com-
mittee members were generally unfamiliar with pharma-
coeconomic concepts and preferred that a complicated
economic model not be used. Results of the expert survey
indicated that there are important differences between
the RCT protocol and Canadian treatment patterns.
These differences include restrictive inclusion/exclusion
criteria, an excess of protocol-driven tests and proce-
dures, and treatment strategies that are not necessarily re-
flective of real-life. The case modeling exercise allowed
for a structured method to hypothesize on the real-world
impact of the product. An ongoing chart review will be
used to confirm these hypotheses. CONCLUSIONS: It is
anticipated that issues surrounding the absence of coun-
try-specific data will continue to plague researchers for
the foreseeable future. Use of this multi-step approach
provides a rigorous method for making conclusions in
the absence of locally acquired evidence.
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OBJECTIVE: To assess systematically, using a panel of
physician experts, the assumptions made for a pharmaco-
economic model regarding the indications, treatment ini-
tiation and decision rules for management of type 2 dia-
betics. METHODS: The panel consisted of 7 physicians
(three family physicians, two internists and two endocri-
nologists) who were randomly selected from a pool of
high-volume prescribers. The panel was contacted by
phone and upon acceptance, they were mailed a 63-item
questionnaire cover clinical criteria for treatment man-
agement, adherence to diabetes guidelines, decision rules
for failure treatment, resource use and tests requested for
drug-naïve and previously treated patients. The question-
naire was developed based on literature review and pilot-
tested between two clinicians for appropriateness. The
ratings were done using a 5-item Likert scale ranging
from “strongly agree” to “strongly disagree”. RESULTS:
All participating physicians completed the questionnaire.
Endocrinologists and internists follow the American Dia-
betes Association guidelines (ADA). Only two family
physicians use the ADA guidelines. The main assump-
tions for the pharmacoeconomic model coincided with
the experts’ opinion, such as the initial treatment for a
drug-naïve type 2 diabetic patient is monotherapy and af-
ter its failure an increased dose followed by addition of
another treatment is recommended. Treatment adjust-
ment is based on glycosylated hemoglobin, post-prandial
glucose or fasting plasma glucose. For any treatment
changes, patient should visit physician office but they are
not usually hospitalized. The presence of side effects is an
indication to decrease the dose. Number and type of lab-
oratory tests are independent of drug-naïve status. There
are no differences in the criteria used for treatment selec-
tion and treatment changes between drug-naïve patients
and previously treated patients. Furthermore experts do
not recommend switching medications. CONCLUSIONS:
An expert panel is a useful tool to assess model assump-
tions.
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OBJECTIVES: When comparing patient management
and patient outcomes, the available services within a
catchment area appear to be a major confounding factor.
The ESMS aims to classify services and measure their ac-
tivity in a standardized way, which opens new opportuni-
ties to adjust for service offer. The ESMS allows to map
the services available in a set of catchment areas and to
identify different profiles. In addition we evaluate the ac-
curacy of the French standardized classification of mental
health services and the applicability of the instrument in
France. METHODS: 171 services in 24 catchment areas
